Q1 met expectations, but the guidance downgrade was a surprise
08/05/25 -"Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained stable. However, profitability fell short of ..."
Pages
62
Language
English
Published on
08/05/25
You may also be interested by these reports :
09/05/25
Sonova’s full-year results slightly exceeded market expectations, with robust growth across both segments. The promising FY2025-26 outlook was well ...
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...